A new study from the Department of Health and Human Services shows that policies in President Donald Trump’s first administration helped lower some patients’ insulin costs below $35 for a 30-day supply.
FOX Business obtained a copy of the new report set to be released as early as Monday. It shows the executive orders signed by Trump in his first term helped push the price of insulin lower.
Trump signed four executive orders aimed at lowering costs of the life-saving treatment on July 24, 2020. The first ordered federally qualified health centers to pass along discounts received by drugmakers, instead of pocketing the benefit. The second allowed state health plans to import “safe” insulin and create a pathway for personal importation waivers at authorized pharmacies. The third banned secret deals with healthcare middlemen so drug manufacturing discounts go directly to customers. The fourth mandated that U.S. consumers pay the lowest price paid by other countries and opened the door for Medicare to negotiate terms of insulin payments.
US SHOULDERS DISPROPORTIONATE COST OF NEW MEDICATIONS, REPORT FINDS
A chart tracking the commercial and Medicare cost of insulin doses shows the policies contributed and almost immediately started lowering the cost of the medication. In fact, well before former President Joe Biden signed the Inflation Reduction Act into law in 2022, the price of a 30-day dose had fallen well below $35. The Act placed a cap on insulin at $35, and the former president often took credit for lowering the cost of the medications.
MERCK, SANOFI ARE LATEST COMPANIES TO ADD MEDICATIONS TO TRUMPRX
“While Joe Biden tried taking credit for $35 insulin, the data is clear: this was President Trump’s success alone, and the second Trump administration continues to harness competition and consumer empowerment with TrumpRx to deliver more relief for everyday Americans,” White House senior deputy press secretary Kush Desai said in a statement.
BRISTOL MYERS SQUIBB ADDING 3 MEDICATIONS ON TRUMPRX
Adam Gluck, the head of U.S. corporate affairs at Sanofi, said during an announcement of $35 insulin doses in September 2025 that “We will continue to work with policymakers and stakeholders across the healthcare system on additional sustainable, long-term solutions to improve access to medicines.”
Novo Nordisk, in January 2024, said: “Novo Nordisk recognizes that some patients find it difficult to pay for healthcare, including insulin. As such, the Company remains committed to reducing the burden of out-of-pocket costs, helping transform the complex pricing system, and fostering better pricing predictability.”
The Trump administration believes the introduction of TrumpRx.gov and use of its tariff policies will further reduce the cost of insulin in the future.
Read the full article here